Collection of Blood Samples in Patients With Non-small Cell Lung Cancer

Overview

This pilot research trial studies the collection of blood samples in monitoring tumor specific mutations in patients with non-small cell lung cancer that has spread to other places in the body or cannot be removed by surgery. Collecting blood samples may help measure the changes in lung cancer, better learn methods to track cancer in the bloodstream, and improve cancer treatments.

Full Title of Study: “Longitudinal Monitoring of Tumor Specific Mutations in Patients With Lung Cancer”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: November 21, 2023

Detailed Description

PRIMARY OBJECTIVES: I. To evaluate the ability of next generation sequencing (NGS) to monitor the evolution of cancer-specific mutations in patients undergoing treatment for non-small cell lung carcinoma and for whom the molecular profile of the tumor cells prior to treatment is known. II. Compare the sensitivity of digital droplet polymerase chain reaction (ddPCR) to that of NGS for detecting the appearance of EGFR T790M mutations in patients treated with an EGFR tyrosine kinase inhibitor. OUTLINE: Patients undergo collection of blood samples at baseline and every 12 weeks for up to 6 times.

Interventions

  • Procedure: Biospecimen Collection
    • Undergo collection of blood samples
  • Other: Laboratory Biomarker Analysis
    • Correlative studies

Arms, Groups and Cohorts

  • Ancillary-Correlative (biospecimen collection)
    • Patients undergo collection of blood samples at baseline and every 12 weeks for up to 6 times.

Clinical Trial Outcome Measures

Primary Measures

  • Blood sample collection for tumor specific mutations study from patients with non-small cell lung cancer
    • Time Frame: Baseline to 3 years
    • Blood samples collected will be used to evaluate the ability of next generation sequencing (NGS) to monitor the evolution of cancer-specific mutations in patients undergoing treatment for non-small cell lung carcinoma and for whom the molecular profile of the tumor cells prior to treatment is known.

Participating in This Clinical Trial

Inclusion Criteria

  • A diagnosis of non-small cell lung carcinoma for which the molecular profile of the primary tumor has been obtained from a block of paraffin-embedded, formalin-fixed tissue that remains available – Zubrod performance status 0 or 1 – Patients must have metastatic or unresectable disease and be starting a new line of systemic treatment at the time of enrollment; there are no constraints regarding the time interval between the initial collection of samples for molecular profiling studies at the time of diagnosis prior to treatment and subsequent collections of circulating cell-free deoxyribonucleic acid (DNA) or circulating tumor cells – Patients must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 – Ability to understand and the willingness to sign a written informed consent; Note: There will be no discrimination between type of treatment or whether they are on continuous versus intermittent therapy Exclusion Criteria:

  • Known severe anemia (hemoglobin [Hb] < 8g/dL) – Patients will be excluded if trackable driver mutations are not identified in the primary tumor tissue

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Southern California
  • Collaborator
    • National Cancer Institute (NCI)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Pamela Ward, MD, Principal Investigator, University of Southern California

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.